---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-039818"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2026-06-02T20:39:40+00:00"
generated_at: "2026-06-02T20:41:08.859678+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arvinas to out-license ARV-806 after completing Phase 1 dose escalation

## Summary
- Completed dose escalation enrollment for ARV-806 Phase 1 trial in KRAS G12D solid tumors.
- Will complete monotherapy dose escalation and share clinical data in 2026.
- Plans to seek out-licensing agreement for any additional ARV-806 trials.
- Cash, equivalents and marketable securities as of March 31, 2026 fund operations into H2 2028.

## SEC filing metadata
- accession: 0001628280-26-039818
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2026-06-02T20:39:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/0001628280-26-039818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/arvn-20260602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-039818
- JSON: https://secwatch.observer/filing/0001628280-26-039818.json
- Plain text: https://secwatch.observer/filing/0001628280-26-039818.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.